Figure 2

Ectopic expression of miR-204 in neuroblastoma cell lines increases sensitivity to cisplatin (CDDP) in vitro. (A, B) Neuroblastoma MYCN-amplified cell lines Kelly and NB1691 were transfected with miR-204 mimics or scrambled negative control (NC) oligonucleotides. At 48 h post transfection, cells were treated for 24 h with 0 to 50 μg ml⁻¹ CDDP. Media were replaced for a further 24 h, and viability determined at 96 h by MTS assays. (C, D) Kelly and NB1691 cells were transfected with an siRNA targeting BCL2 or a siRNA negative control oligonucleotide (siNEG NC), or miR-204 mimics or scrambled negative control (scrambled NC) oligonucleotides. At 48 h post transfection, cells were treated for 24 h with or without 5 μg ml⁻¹ CDDP. Media were replaced for a further 24 h, and viability determined at 96 h by MTS assays. Percentage survival was determined relative to either untreated siNEG NCs or untreated scrambled NCs. All graphed values represent (mean value ±s.e.m.) biological replicate experiments (n=3–5) with six technical replicates, and differences in viability were analysed by two-sided Student’s t-tests.